ME03800B - Heteroaril amidi kao inhibitori proteinske agregacije - Google Patents

Heteroaril amidi kao inhibitori proteinske agregacije

Info

Publication number
ME03800B
ME03800B MEP-2020-148A MEP2020148A ME03800B ME 03800 B ME03800 B ME 03800B ME P2020148 A MEP2020148 A ME P2020148A ME 03800 B ME03800 B ME 03800B
Authority
ME
Montenegro
Prior art keywords
inhibitors
protein aggregation
heteroaryl amides
heteroaryl
amides
Prior art date
Application number
MEP-2020-148A
Other languages
German (de)
English (en)
French (fr)
Inventor
Emily M Stocking
Wolfgang Wrasidlo
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52484559&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME03800(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of ME03800B publication Critical patent/ME03800B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
MEP-2020-148A 2014-01-29 2015-01-28 Heteroaril amidi kao inhibitori proteinske agregacije ME03800B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461933246P 2014-01-29 2014-01-29
US201462078895P 2014-11-12 2014-11-12
EP18156929.4A EP3348556B1 (en) 2014-01-29 2015-01-28 Heteroaryl amides as inhibitors of protein aggregation

Publications (1)

Publication Number Publication Date
ME03800B true ME03800B (me) 2021-04-20

Family

ID=52484559

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2020-148A ME03800B (me) 2014-01-29 2015-01-28 Heteroaril amidi kao inhibitori proteinske agregacije

Country Status (37)

Country Link
US (3) US9738635B2 (me)
EP (2) EP3099684B8 (me)
JP (2) JP6619741B2 (me)
KR (1) KR102383038B1 (me)
CN (2) CN111039939B (me)
AP (1) AP2016009347A0 (me)
AU (1) AU2015211119B2 (me)
BR (2) BR112016017344B1 (me)
CA (1) CA2937967C (me)
CL (1) CL2016001918A1 (me)
CR (1) CR20160394A (me)
CY (2) CY1120348T1 (me)
DK (2) DK3348556T3 (me)
EA (1) EA032374B1 (me)
EC (1) ECSP16070327A (me)
ES (2) ES2675301T3 (me)
HK (1) HK1231470A1 (me)
HR (2) HRP20180813T1 (me)
HU (2) HUE050964T2 (me)
IL (1) IL246987B (me)
LT (2) LT3099684T (me)
ME (1) ME03800B (me)
MX (1) MX2016009896A (me)
MY (1) MY187450A (me)
NZ (1) NZ722487A (me)
PE (1) PE20161393A1 (me)
PH (1) PH12016501493A1 (me)
PL (2) PL3348556T3 (me)
PT (2) PT3348556T (me)
RS (2) RS57533B1 (me)
SA (1) SA516371579B1 (me)
SG (1) SG11201606108RA (me)
SI (2) SI3099684T1 (me)
TR (1) TR201809440T4 (me)
UA (1) UA118209C2 (me)
WO (1) WO2015116663A1 (me)
ZA (1) ZA201605246B (me)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3348556T3 (da) 2014-01-29 2020-08-03 UCB Biopharma SRL Heteroarylamider som hæmmere af proteinaggregering
US10975066B2 (en) 2015-07-29 2021-04-13 UCB Biopharma SRL Bis-heteroaryl derivatives as modulators of protein aggregation
CN107625767A (zh) * 2016-11-25 2018-01-26 刘淑兰 一种治疗慢性盆腔炎的药物
US10889584B2 (en) * 2017-01-26 2021-01-12 UCB Biopharma SRL Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation
KR20190112031A (ko) * 2017-01-26 2019-10-02 유씨비 바이오파마 에스피알엘 단백질 응집의 조절제로서의 알콕시 비스-헤테로아릴 유도체
ES2882285T3 (es) 2017-01-26 2021-12-01 Ucb Biopharma Sprl Derivados de bis-heteroarilo como moduladores de la agregación de proteínas
CA3062749A1 (en) * 2017-05-12 2018-11-15 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Compounds for use in the treatment or prevention of melanoma
US11505528B2 (en) 2017-08-04 2022-11-22 Axial Therapeutics, Inc. Inhibitors of microbially induced amyloid
EP3703730A4 (en) * 2017-10-31 2022-01-12 Loma Linda University METHODS OF TREATMENT OF TRAUMATIC BRAIN DAMAGE
WO2020041331A1 (en) 2018-08-20 2020-02-27 Arvinas Operations, Inc. Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases
WO2023125376A1 (zh) * 2021-12-27 2023-07-06 上海京新生物医药有限公司 作为蛋白质聚集抑制剂的稠合双环杂芳基酰胺化合物
GB202213796D0 (en) * 2022-09-21 2022-11-02 Wista Lab Ltd Tau aggregation inhibitors
WO2024094731A1 (en) * 2022-11-02 2024-05-10 Ac Immune Sa Novel compounds for the diagnosis of tdp-43 proteinopathies

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1463997A (en) * 1995-12-22 1997-07-17 Acea Pharmaceuticals, Inc. Subtype-selective nmda receptor ligands and the use thereof
JP2006508997A (ja) * 2002-11-28 2006-03-16 シエーリング アクチエンゲゼルシャフト Ｃｈｋ−、Ｐｄｋ−およびＡｋｔ−阻害性ピリミジン、それらの製造および薬剤としての使用
CN101385722A (zh) * 2003-02-27 2009-03-18 乔安妮·麦克劳林 预防、治疗和诊断蛋白聚集疾病的方法
KR20070018824A (ko) * 2003-12-19 2007-02-14 브리스톨-마이어스 스큅 컴퍼니 카나비노이드 수용체 조절제인 아자비사이클릭헤테로사이클
TW200528455A (en) * 2003-12-19 2005-09-01 Bristol Myers Squibb Co Azabicyclic heterocycles as cannabinoid receptor modulators
PT1697371E (pt) * 2003-12-19 2007-08-03 Bristol Myers Squibb Co Heterocíclos azabicíclicos como moduladores do receptor de canabinóides
GEP20104906B (en) * 2004-08-26 2010-02-25 Pfizer Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
EP1797084A1 (en) * 2004-09-20 2007-06-20 4Sc Ag NOVEL HETEROCYCLIC NF-kB INHIBITORS
SE0403119D0 (sv) * 2004-12-21 2004-12-21 Astrazeneca Ab Therapeutic agents
US20100168102A9 (en) * 2005-07-11 2010-07-01 Devgen Nv Amide Derivatives as Kinase Inhibitors
CN101233119A (zh) * 2005-07-29 2008-07-30 4Sc股份有限公司 新型杂环NF-κB抑制剂
MX2008011696A (es) * 2006-03-15 2008-11-12 4Sc Ag Inhibidores de nf-kb heterociclicos novedosos.
EP2081892A4 (en) * 2006-11-17 2014-03-05 Donald F Weaver COMPOUNDS AND METHOD FOR THE TREATMENT OF PROTEIN DISAPPEARANCE
US8450481B2 (en) * 2007-06-14 2013-05-28 The Regents Of The University Of California Compounds for inhibiting protein aggregation, and methods for making and using them
WO2010068452A1 (en) * 2008-11-25 2010-06-17 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
GB0910003D0 (en) * 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
JP2013508350A (ja) * 2009-10-20 2013-03-07 ファイザー・インク ガンマ−セクレターゼモジュレーターとしての新規なヘテロアリールイミダゾールおよびヘテロアリールトリアゾール
WO2011084642A1 (en) 2009-12-16 2011-07-14 Neuropore Therapies, Inc. Compound suitable for the treatment of synucleopathies
GB201021103D0 (en) * 2010-12-13 2011-01-26 Univ Leuven Kath New compounds for the treatment of neurodegenerative diseases
WO2013134371A1 (en) 2012-03-06 2013-09-12 Neuropore Therapies, Inc. Methods and compounds to be used in the treatment of neurodegenerative diseases
US9527852B2 (en) 2012-03-28 2016-12-27 Neuropore Therapies, Inc. Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation
BR112015001096A2 (pt) 2012-07-16 2017-06-27 Neuropore Therapies Inc derivados de di e tri-heteroaril como inibidores de agregação de proteína
DK3348556T3 (da) 2014-01-29 2020-08-03 UCB Biopharma SRL Heteroarylamider som hæmmere af proteinaggregering
US10975066B2 (en) 2015-07-29 2021-04-13 UCB Biopharma SRL Bis-heteroaryl derivatives as modulators of protein aggregation
US10889584B2 (en) 2017-01-26 2021-01-12 UCB Biopharma SRL Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation
ES2882285T3 (es) 2017-01-26 2021-12-01 Ucb Biopharma Sprl Derivados de bis-heteroarilo como moduladores de la agregación de proteínas

Also Published As

Publication number Publication date
CR20160394A (es) 2016-11-01
IL246987B (en) 2021-12-01
US11078196B2 (en) 2021-08-03
EP3099684A1 (en) 2016-12-07
PT3099684T (pt) 2018-10-22
KR20160113287A (ko) 2016-09-28
CA2937967C (en) 2022-07-26
NZ722487A (en) 2022-04-29
AU2015211119B2 (en) 2019-05-30
UA118209C2 (uk) 2018-12-10
WO2015116663A1 (en) 2015-08-06
BR112016017344B1 (pt) 2023-05-16
EP3348556B1 (en) 2020-04-29
DK3348556T3 (da) 2020-08-03
ES2675301T3 (es) 2018-07-10
HUE050964T2 (hu) 2021-01-28
EA032374B1 (ru) 2019-05-31
TR201809440T4 (tr) 2018-07-23
EP3099684B8 (en) 2018-07-04
SI3348556T1 (sl) 2020-10-30
BR122018001892B1 (pt) 2023-05-02
SI3099684T1 (en) 2018-08-31
SA516371579B1 (ar) 2019-07-16
CN111039939B (zh) 2023-09-19
AU2015211119A1 (en) 2016-08-11
RS60547B1 (sr) 2020-08-31
CY1123374T1 (el) 2021-12-31
CA2937967A1 (en) 2015-08-06
AP2016009347A0 (en) 2016-07-31
PL3348556T3 (pl) 2020-11-02
ES2808978T8 (es) 2021-03-22
BR112016017344A2 (pt) 2017-10-03
CN106132960B (zh) 2019-12-17
CY1120348T1 (el) 2019-07-10
CL2016001918A1 (es) 2017-01-13
US20190308965A1 (en) 2019-10-10
US20160207912A1 (en) 2016-07-21
MX2016009896A (es) 2017-01-11
US10358443B2 (en) 2019-07-23
US9738635B2 (en) 2017-08-22
WO2015116663A8 (en) 2016-09-15
SG11201606108RA (en) 2016-08-30
PL3099684T3 (pl) 2018-09-28
PH12016501493B1 (en) 2017-02-06
HRP20201107T8 (hr) 2020-12-11
HRP20180813T1 (hr) 2018-07-27
LT3348556T (lt) 2020-08-10
MY187450A (en) 2021-09-22
JP6783900B2 (ja) 2020-11-11
IL246987A0 (en) 2016-09-29
ZA201605246B (en) 2022-05-25
PH12016501493A1 (en) 2017-02-06
JP6619741B2 (ja) 2019-12-11
JP2019163321A (ja) 2019-09-26
CN111039939A (zh) 2020-04-21
RS57533B1 (sr) 2018-10-31
KR102383038B1 (ko) 2022-04-05
ES2808978T3 (es) 2021-03-02
HUE040274T2 (hu) 2019-03-28
JP2017505779A (ja) 2017-02-23
EP3348556A1 (en) 2018-07-18
EA201691529A1 (ru) 2017-01-30
PT3348556T (pt) 2020-07-27
EP3099684B1 (en) 2018-04-04
AU2015211119A8 (en) 2016-12-15
DK3099684T3 (en) 2018-07-16
LT3099684T (lt) 2018-06-25
ECSP16070327A (es) 2018-05-31
HRP20201107T1 (hr) 2020-10-30
CN106132960A (zh) 2016-11-16
HK1231470A1 (zh) 2017-12-22
PE20161393A1 (es) 2017-01-08
US20180093979A1 (en) 2018-04-05

Similar Documents

Publication Publication Date Title
HRP20201107T8 (hr) Heteroaril amidi kao inhibitori proteinske agregacije
ZA201702402B (en) Heteroaryl compounds as irak inhibitors and uses thereof
HK1245774A1 (zh) Copanlisib及其二鹽酸鹽的合成
HRP20190527T1 (hr) Sinteza kopanlisiba i njegove dihidrokloridne soli
IL251568A0 (en) Aminopyridine substances are effective as prenylation inhibitors in proteins
GB201415425D0 (en) Small molecule inhibitors of classiv bromodomain proteins